摘要
1型糖尿病是一种由淋巴细胞介导胰岛β细胞发生进展性破坏导致的自身免疫病,近年来发病率迅速增长,患者以儿童、青少年为主。目前,以T淋巴细胞、B淋巴细胞、细胞因子为目标的靶向免疫治疗1型糖尿病已获得长足进展,此文针对不同靶点的各种药物对1型糖尿病的临床前期、临床研究疗效以及免疫预防方案进行综述。
Type 1 diabetes mellitus(T1DM)is an autoimmune disease characterized by lymphocyte-mediated progressive destruction of pancreaticβcells.T1DM mainly affects children and young adults,and its incidence has increased rapidly in recent years.At present,the immunotherapy targeting T-lymphocytes,B-lymphocytes and cytokines has made great progress in T1DM treatment.This article reviews the preclinical,clinical efficacies and immunoprophylaxis effects of different targeted drugs for T1DM.
作者
吴宇清
江妍斐(综述)
张进安(审校)
Wu Yuqing;Jiang Yanfei;Zhang Jin’an(Graduate School,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Depertment of Endocrinology&Rheumatology,Shanghai University of Medicine&Health Sciences Af filiated Zhoupu Hospital,Shanghai 201318,China;Shanghai University of Traditional Chinese Medicine,Shanghai201203,China)
出处
《国际生物制品学杂志》
CAS
2022年第5期266-271,共6页
International Journal of Biologicals
基金
国家自然科学基金(81873636)
上海市医学重点专科项目资助(ZK2019C09)
浦东新区第二轮医学学科建设项目-临床特色学科(PWYts2021-09)
上海健康医学院甲状腺病临床研究中心(20MC20200002)。
关键词
糖尿病
1型
靶向
免疫治疗
免疫预防
Diabetes mellitus,type 1
Targeting
Immunotherapy
Immunoprophylaxis
